tris[(propargyloxy)methyl]aminomethane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tris[(propargyloxy)methyl]aminomethane
• 英文别名: 1,3-bis(prop-2-yn-1-yloxy)-2-((prop-2-yn-1-yloxy)methyl)propan-2-amine；tri-O-propargyl-tris(hydroxymethyl)aminomethane；1,3-Bis(prop-2-yn-1-yloxy)-2-((prop-2-yn-1-yloxy)methyl)propan-2-amine；1,3-bis(prop-2-ynoxy)-2-(prop-2-ynoxymethyl)propan-2-amine
• 化学式: C₁₃H₁₇NO₃
• 分子量: 235.283
• InChiKey: SUBOASRXOYLNNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  53.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tris[(propargyloxy)methyl]aminomethane 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成
  参考文献：
  名称：

  Synthesis and Evaluation of a Photoactive Probe with a Multivalent Carbohydrate for Capturing Carbohydrate–Lectin Interactions

  摘要：

  Lectins are ubiquitous carbohydrate-binding proteins of nonimmune origin that are characterized by their specific recognition of defined monosaccharide or oligosaccharide structures. However, the use of carbohydrates to study lectin has been restricted by the weak binding affinity and noncovalent character of the interaction between carbohydrates and lectin. In this report, we designed and synthesized a multifunctional photoaffinity reagent composed of a trialkyne chain, a masked latent amine group, and a photoreactive 3-trifluoromethyl-3phenyl-diazirine group in high overall yield. Two well-defined chemistries, Huisgen-Sharpless click chemistry and amide bond coupling, were the key steps for installing the multivalent character and tag in our designed photoaffinity probe. The photolabeling results demonstrated that the designed probe selectively labeled the target lectin, RCA(120) (Ricinus communis Agglutinin), in an E. coli lysate and an asialoglycoprotein receptor (ASGP-R) on intact HepG2 cell membranes. Moreover, the probe also enabled the detection of weak protein protein interactions between RCA(120) and ovalbumin (OVA).

  DOI：

  10.1021/bc400306g
• 作为产物：
  描述：

  N-(tert-butyloxycarbonyl)tris[(propargyloxy)methyl]aminomethane 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 tris[(propargyloxy)methyl]aminomethane
  参考文献：
  名称：

  单击激发的六价和八价外围半乳糖基化糖类树状大分子的合成及其可能的治疗应用†

  摘要：

  Cu（I）催化的叠氮化物-炔烃1,3-偶极环加成反应（CuAAC）已用于合成新型糖树枝状聚合物，该糖类树枝状聚合物含有以6和18个外围β- D-吡喃半乳糖苷单元为中心的刚性六炔丙氧基苯中心核。使用核磁共振和红外光谱，基质辅助激光解吸/电离质谱和尺寸排阻色谱法很好地阐明了新型糖类树状聚合物和中间体的结构。研究了已开发的糖类树状大分子的治疗评估，发现它们具有良好的潜力，可作为抗菌剂，抗生物膜和抗肿瘤剂。

  DOI：

  10.1039/c9nj02564b

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• 一种基于分子梭的诊疗型纳米药物
  申请人：复旦大学

  公开号：CN111012743B

  公开（公告）日：2022-07-08

  本发明属生物技术领域，涉及一种基于分子梭的新型诊疗型纳米药物。本发明通过点击化学反应将药物连接到分子梭客体分子两端，利用药物分子尺寸效应，使分子梭客体难以被分子梭主体识别穿环，而在肿瘤还原性微环境中，药物释放同时解放分子梭客体，使其可以被分子梭主体迅速、精准、特异识别并穿环，形成一种梭形近红外超分子探针，可用于体外细胞水平或体内动物水平实时表征药物的释放行为。
• SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
  申请人：Pfizer Inc.

  公开号：US20150329555A1

  公开（公告）日：2015-11-19

  Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.

  公式（A）的化合物在本文件中被描述，以及它们用于治疗由药物组合物介导的疾病、状况和/或紊乱的使用，以及它们作为阿索糖蛋白受体（ASGPR）靶向剂的使用。
• 6-Azido hyacinthacine A₂gives a straightforward access to the first multivalent pyrrolizidine architectures
  作者：Giampiero D'Adamio、Camilla Parmeggiani、Andrea Goti、Antonio J. Moreno-Vargas、Elena Moreno-Clavijo、Inmaculada Robina、Francesca Cardona

  DOI：10.1039/c4ob01117a

  日期：——

  The synthesis of the first multivalent pyrrolizidine iminosugars is reported. The key azido intermediates 4 and 31 were prepared after suitable synthetic elaboration of the cycloadduct obtained from 1,3-dipolar cycloaddition of D-arabinose derived nitrone to dimethylacrylamide. The key step of the strategy was the stereoselective installation of an azido moiety at C-6 of the pyrrolizidine skeleton. The click reaction with different monovalent and dendrimeric alkyne scaffolds allowed the preparation of a library of new mono- and multivalent pyrrolizidine compounds that were preliminarily assayed as glycosidase inhibitors towards a panel of commercially available glycosyl hydrolases.

  首次报道了多价吡咯并吡嗪亚胺糖的合成。通过对从D-阿拉伯糖衍生的亚硝基与二甲基丙烯酰胺进行1,3-偶极环加成反应得到的环加成产物进行适当的合成改良，制备了关键的叠氮中间体4和31。该策略的关键步骤是在吡咯并吡嗪骨架的C-6位进行立体选择性的叠氮基团的引入。通过与不同的一价和树枝状炔基骨架进行点击反应，制备了一系列新的单价和多价吡咯并吡嗪化合物，这些化合物被初步检测为对商业可得的糖基水解酶的糖苷酶抑制剂。
• [EN] TARGETED PLASMA PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES DE PLASMA
  申请人：NOVARTIS AG

  公开号：WO2021156792A1

  公开（公告）日：2021-08-12

  The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

  本发明涉及双功能化合物及利用这种双功能化合物通过溶酶体降解降低细胞外靶分子血浆水平的用途。这种双功能化合物具有与细胞表面受体配体共价连接的配体，该配体能够结合到细胞外靶分子（例如生长因子、细胞因子、趋化因子、激素、神经递质、外壳蛋白、可溶性受体、细胞外分泌蛋白、抗体、脂蛋白、外泌体、病毒、细胞或血浆膜蛋白的配体），其中细胞表面受体与受体介导的内吞作用相关联，包括以阿斯利康蛋白受体（ASGPR）介导的溶酶体降解和甘露糖-6-磷酸（M6PR）介导的溶酶体降解。本文还提供了包括这种双功能化合物的药物组合物以及利用这种双功能化合物治疗通过细胞外分子介导的疾病或紊乱的方法。